Bridgeway Capital Management, LLC Black Diamond Therapeutics, Inc. Transaction History
Bridgeway Capital Management, LLC
- $4.76 Billion
- Q1 2024
A detailed history of Bridgeway Capital Management, LLC transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Bridgeway Capital Management, LLC holds 173,000 shares of BDTX stock, worth $826,940. This represents 0.02% of its overall portfolio holdings.
Number of Shares
173,000
Previous 192,000
9.9%
Holding current value
$826,940
Previous $539,000
62.71%
% of portfolio
0.02%
Previous 0.01%
Shares
7 transactions
Others Institutions Holding BDTX
# of Institutions
93Shares Held
36.5MCall Options Held
29.6KPut Options Held
5K-
Bellevue Group Ag Kuesnacht, V88.52MShares$40.7 Million0.68% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD6.73MShares$32.1 Million0.02% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$21.3 Million1.58% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.91MShares$9.11 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.6MShares$7.66 Million0.99% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $174M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...